BLACK DIAMOND THERAPEUTICS I

Black Diamond’s new Phase 2 data for brain‑penetrant EGFR inhibitor silevertinib spark FDA optimism for accelerated approval, yet the company’s negative EPS and modest market cap signal high risk for investors.